RT Journal Article
SR Electronic
T1 Serum sickness reaction to obinutuzumab in a patient with chronic lymphocytic leukaemia
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e245557
DO 10.1136/bcr-2021-245557
VO 14
IS 12
A1 Oday Elmanaseer
A1 Alzira R M Avelino
A1 Amin Azem
A1 Mihir Raval
YR 2021
UL http://casereports.bmj.com/content/14/12/e245557.abstract
AB Serum sickness (SS) is a known phenomenon; however, it is commonly missed due to vague symptoms, and is usually confounded by other aetiologies that present similarly. Obinutuzumab is a novel anti-CD20 antibody agent that has been approved for chronic lymphocytic leukaemia (CLL) treatment. At the time of approval, it was not linked to SS; however, this phenomenon has been recognised with other anti-CD20 agents like rituximab. SS remains a rare entity, but it is important to be recognised accurately and quickly in the appropriate circumstances, so that effective treatment with corticosteroids can be initiated to alleviate inflammatory symptoms. Here we present a patient with CLL who developed maculopapular rash, fever and polyarthritis and elevated inflammatory markers consistent with serum sickness triggered by obinutuzumab and was effectively treated with corticosteroids.